Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Crescent Biopharma (CBIO) Other Operating Expenses (2024 - 2025)

Crescent Biopharma (CBIO) has disclosed Other Operating Expenses for 7 consecutive years, with $130.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Other Operating Expenses changed N/A to $130.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $130.8 million, a N/A change, with the full-year FY2025 number at $163.5 million, up 13245.58% from a year prior.
  • Other Operating Expenses was $130.8 million for Q4 2025 at Crescent Biopharma, up from $1.2 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $130.8 million in Q4 2025 to a low of -$1.0 in Q4 2021.
  • A 4-year average of $26.4 million and a median of $1.0 in 2021 define the central range for Other Operating Expenses.